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Cancer is a worldwide health problem; in 2018 9.6 million people died of cancer, meaning that about 1 in 6 deaths was caused by it. 
The challenge with cancer drug therapy has been the development of cancer drugs that are effective against cancer but are not 
harmful to the healthy cells. One of the solutions to this has been antibody-drug conjugates (ADCs), where a cytotoxic drug is bound 
to an antibody. The antibody binds to specific antigen present on the surface of the cancer cell, thus working as a vessel to carry the 
drug specifically to the cancer cells. 
 
Monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are mitosis preventing cancer drugs. The auristatins are 
pentapeptides that were developed from dolastatin 10. MMAE consist of monomethyl valine (MeVal), valine (Val), dolaisoleiune (Dil), 
dolaproine (Dap) and norephedrine (PPA). MMAF has otherwise similar structure, but norephedrine is replaced by phenylalanine 
(Phe). They prevent cell division and cancer cell proliferation by binding to microtubules and are thus able to kill any kind of cell. By 
attaching the auristatin to an antibody that targets cancer cells, they can effectively be used in the treatment of cancer.   
 
MMAE and MMAF exist as two conformers in solution, namely as cis- and trans-conformers. The trans-conformer resembles the 
biologically active conformer. It was recently noted that in solution 50-60 % of the MMAE and MMAF-molecules exist in the biologically 
inactive cis-conformer. The molecule changes from one conformer to the other by the rotation of an amide bond. However, this takes 
several hours in body temperature. As the amount of the cis-conformer is significant, the efficacy of the drug is decreased, and the 
possibility of side effects is increased. It is possible that the molecule leaves the cancer cell in its inactive form, migrates to healthy 
cells and tissue, and transforms to the active form there, damaging the healthy cell.  
 
The goal of this study was to modify the structure of the auristatins so that the cis/trans-equilibrium would change to favor the 
biologically active trans-conformer. The modifications were done virtually, and the relative energies were computed using high-level 
quantum chemical methods, at density functional theory (DFT), 2nd order perturbation theory (MP2) and coupled cluster levels. 
Intramolecular interactions were analyzed computationally, employing symmetry-adapted perturbation theory and the non-covalent 
interactions analysis. The results suggest that simple halogenation of the benzene ring para-position is able to significantly shift the 
cis/trans-equilibrium to favor the trans-conformer. This is due to changes in intramolecular interactions that favor the trans-conformer 
after halogenation. For example, the NCI analysis shows that the halogen atom invokes stabilizing intramolecular interactions with 
the Dil amino acid; there is no such interaction between the para-position hydrogen and Dil in the original molecules. We also 
performed docking studies that show that the halogenated molecules can bind to microtubules, thus confirming that the modified 
structures have potential to be developed into new, more efficient and safe cancer drugs. 
 
The most promising drug candidates are Cl-MMAF, F-MMAF, and F-MMAE where 94, 90, and 79 % of the molecule is predicted to 
exist in the biologically active trans-conformer, respectively. 
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Abbreviations 
MMAE  monomethyl auristatin E 
MMAF  monomethyl auristatin F 
NMR   nuclear magnetic resonance 
CD30 cluster of differentiation 30,1 also known as TNFSF8, tumor necrosis factor 
receptor superfamily, member 8; an antigen/protein 
CD79b  cluster of differentiation 79b; an antigen/protein 
FDA   United States Food and Drug Administration 
EU    European Union 
EMA   European Medicines Agency 
MHLW  Japanese Ministry for Health, Labour and Welfare 
ADC    antibody-drug conjugate  
GTP   guanosine triphosphate 
GDP   guanosine diphosphate 
SAR   structure-activity relationship 
TLL    tubulin-tyrosine ligase 
RB3    stathmin-like protein B3 
PDB    Protein Data Bank 
QM   quantum chemistry 
HF   Hartree-Fock 
MP   Møller-Plesset 
CC   coupled cluster  
DFT   density functional theory 
SCF   self-consisted field  
SCS-MP2  spin-component scaled second order Møller-Plesset 
CCSD(T)  coupled cluster singles and doubles with perturbative triples correction 
DLPNO  domain based local pair natural orbital 
LSDA    local spin density approximation 
GGA    generalized gradient approximation 
TPSSh   hybrid Tao−Perdew−Staroverov−Scuseria density functional 
DFT-D3(BJ)  3rd generation dispersion correction to DFT with Becke-Johnson damping 
SAPT   symmetry adapted perturbation theory 
GTO   Gaussian-type orbital 
NCI   non-covalent interaction 
RMSD   root-mean-square deviation 
def2-QZVPPD  2nd default doubly polarized quadruple-zeta valence Karlsruhe basis set 
augmented with diffuse functions 
def2-TZVPPD  2nd default doubly polarized triple-zeta valence Karlsruhe basis set 
augmented with diffuse functions 
RESP    restrained electrostatic potential 
VMD   Visual Molecular Dynamics  
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1 Introduction 
 
In 2018 9.6 million people died of cancer worldwide, meaning that about 1 in 6 deaths was due to 
cancer.2, 3 In 2016 around 34 000 new cancer diagnoses were done in Finland4  and during their 
lifetime almost one third of Finns will get cancer.5 Cancer is not just one disease, but a group of 
diseases.6 When a cell undergoes DNA-damage or mutation that greatly alters its function, the cell 
would normally die by apoptosis (controlled cell death) induced by internal signals and signals 
from neighboring cells. In some cases, the cell changes in a way that it is able to avoid these safety 
measures and it starts to proliferate rapidly, causing cancer. The main treatment methods for cancer 
include surgery, radiotherapy and chemotherapy or a combination of these.7  
 
Cancer drugs are usually divided into cell cycle specific and nonspecific drugs.8 Cancer cells 
proliferate faster than regular cells, meaning that they go through the different cell cycle phases 
faster than normal cells.6 This allows for drug treatment strategies that target certain cell cycle 
phases.8 For example, for the cell to undergo cell division, the DNA needs to be doubled. This 
process can be targeted with antimetabolites that disturb DNA synthesis. Antimitotic agents, drugs 
that prevent cell division, are another example of phase specific cancer drugs.  
 
Since many cancer drugs prevent cell division, their side-effects are due to their effects on the 
normal, quickly dividing cell-types of the body.8  Such cell-types are for example cells of the bone 
marrow, hair follicle cells, and cells of the mucous membrane (intestinal epithelium). Therefore, 
common side-effects of cancer drugs include neutropenia, thrombocytopenia, hair loss, ulceration 
of the oral mucosa, and diarrhea. Opportunistic infections are also possible since the patient’s 
immune system is weakened due to the bone marrow effects. Cancer drugs also have specific side-
effects, for example microtubule binding antimitotic agents often cause peripheral neuropathy.9-11  
 
In this work we concentrate on the antimitotic drugs monomethyl auristatin E (MMAE) and 
monomethyl auristatin F (MMAF). They are cell toxic substances that can be used in the treatment 
of cancer. They bind to microtubules, long protein filaments that are a part of the cell cytoskeleton 
(Figure 1).6 Microtubules are hollow tubes formed from tubulin subunits and the site where MMAE 
and MMAF bind is called the vinca domain.12-14 Binding to the vinca domain disturbs the normal 
behavior of microtubules preventing cell division.15  
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Figure 1. A cell in mitosis, the microtubules (in green) pull the chromosomes (in blue) apart to 
form two new cells with equal number of chromosomes. Photo by Nasser Rusan16 
 
It was recently found that MMAE and MMAF exist as two distinct isomers in solution, denoted cis 
and trans. In their trans-forms the molecules bind to the microtubules preventing their normal 
function. This is a desired effect in cancer cells but causes adverse effects in healthy tissue. The 
precise three-dimensional molecular structures of the MMAE and MMAF conformers and their 
relative concentrations in solution was investigated by Johansson et al.17 using both NMR-
spectroscopy (nuclear magnetic resonance) and computational methods. According to the results, 
50-60 % of the drug molecules exist in their biologically inactive cis-conformer in solution. The 
cis-conformer changes to the trans-conformer by rotation of an amide bond, but this takes several 
hours in body temperature. Thus, it is possible that the drug leaves the target cell in its inactive 
form, enters into a healthy cell and changes into the active trans-conformer. Inside the healthy cell 
the molecule can bind to its target, causing side-effects.  
 
The goal of this study was to modify the structure of MMAE and MMAF so that the trans-
conformer would be the more stable conformer. If the cis/trans-equilibrium could be shifted more 
toward the trans-conformer, more of the drug would be in its active form when it reaches the cancer 
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cell. This could potentially increase the efficiency of the drug and lead to a smaller required drug 
dosage. It could also improve safety of the drug, both because smaller dosage would be needed and 
because the drug would bind to the target when it reaches it and not migrate to healthy cells.  
 
2 Background 
 
Currently, there is one commercially available drug containing MMAE on the market in Europe. 
This drug, Adcetris, contains MMAE combined with an antibody (brentuximab vedotin). It is 
indicated for the treatment of adult patients with CD30-positive Hodgkin lymphoma, systemic 
anaplastic large cell lymphoma or CD30 positive cutaneous T-cell lymphoma.18 CD30 is a receptor 
molecule whose function regulates proliferation and apoptosis of the cell.19 A cancer where the 
malignant cells express CD30 protein more than regular cells of the body is called a CD30-positive 
cancer. Similarly, MMAE has been attached to an antibody that targets CD79b antigen (known as 
polatuzumab).11, 20-22 Polatuzumab vedotin was approved by the United States Food and Drug 
Administration (FDA) in June 2019 for the treatment of diffuse large B-cell lymphoma in 
combination with other chemotherapy agents and after the disease has progressed or returned after 
at least two prior therapies.23 MMAE attached to an antibody is known by the name vedotin and 
MMAF by the name mafodotin.24 As of 201925 there are several clinical trials for vedotin/MMAE 
and mafodotin/MMAF with different antibodies and at different study phases.  
 
A disease affecting less than 5 in every 10 000 people in the European Union (EU) is deemed a 
rare disease.26  Over a third of all rare disease medicine are cancer medicine. For some rare diseases 
there is no effective treatment available. Development of new treatments is hindered by high 
production costs and scattered patient populations. To encourage rare disease drug development 
the European Medicines Agency (EMA) may grant an orphan designation to a new medicine in 
development. Medicines with orphan designation are offered incentives such as protocol 
assistance, reduced fees (for regulatory activities), access to centralized authorization procedure 
and 10 years of market exclusivity by the European Union.27 Smaller pharmaceutical companies 
are offered additional incentives. EU works together with FDA and MHLW (Japanese Ministry for 
Health, Labour and Welfare) on orphan designations. Adcetris received an orphan drug designation 
in 2009.28 Currently there is one MMAE containing (polatuzumab vedotin)29 and two MMAF 
containing30, 31 orphan designated medicines in development.  
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2.1 Cancer Drugs, Antibody-Drug Conjugates (ADC) 
 
At the beginning of the 20th century Nobel laureate Paul Ehrlich developed the concept 
“Zauberkugeln” or “magic bullets”.32  These magic bullets where envisioned as drug molecules 
that specifically kill the target cells without causing harm to the healthy cells.33, 34  The problem 
with developing cancer drugs has been the fact that cancer cells do not differ much from the healthy 
cells of the body. Thus, the challenge has been to produce drugs that would specifically kill cancer 
cells without harming normal cells. However, it has been recognized that some cancer cells express 
certain proteins more than the regular cells of the body.6, 35  This has enabled the development of 
antibody-drug conjugates (ADC) where a cytotoxic drug is combined with an antibody that targets 
those proteins.36 The operating principles and components of an ADC are shown in Figure 2. In 
the body the ADC migrates to the target cell and the antibody binds to the target antigen at the 
surface of the cell.35, 37 The ADC is then taken into the cell by endocytosis. Inside the cell the 
cytotoxic agent is released from the antibody and the free drug binds to its target, inducing cell 
death. Thus, ADCs work like the magic bullets Ehrlich envisioned. 
 
The properties of the warhead (cytotoxic agent), the antibody and the linker all affect the efficiency, 
toxicity and other properties of the ADC.36, 38-40 The efficiency of MMAE39 and MMAF40 have 
been increased by combining them to the right antibody with a suitable linker. For example, 
brentuximab vedotin (Adcetris) is an ADC consisting of cell toxic MMAE attached by a linker to 
an antibody targeting CD30 antigen.10, 18, 41  
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Figure 2. Structure and mechanism of an antibody-drug conjugate (ADC). Figure adapted from 17.  
 
Microtubules are part of the cell cytoskeleton and they provide structure, enable movement, 
intracellular transportation, and signaling, as well as play a crucial role in cell division (mitosis) 
(Figure 1).6 A microtubule is a hollow tube. Its wall is formed by αβ-tubulin dimers in rows, with 
13 tubulin subunits forming the circle (Figure 3). Microtubules grow from a centrosome, a cell 
organelle that contains rings formed by γ-tubulin. αβ-tubulin dimers bind to γ-tubulin from the α-
end (minus end) and the microtubule grows from the β-end (plus end). A guanosine triphosphate 
molecule (GTP) is bound to each αβ-tubulin dimer and at some time after the dimer has been added 
to the microtubule the GTP hydrolyses to GDP (guanosine diphosphate). The microtubule keeps 
growing as long as the plus end tubulin dimers have only GTP molecules (GTP cap). GTP 
containing tubulins are more stable and pack more tightly than the GDP containing tubulin dimers. 
Occasionally a GTP in the GTP cap spontaneously hydrolyses to a GDP molecule causing the 
microtubule to depolymerize rapidly. This behavior is known as the dynamic instability of 
microtubules. The microtubule becomes stable when it binds to a cell organelle.  
 
 
8 
 
 
Figure 3. Microtubule is a hollow tube that is formed form αβ-tubulin dimers. The cross section 
shows 13 tubulin units in a ring.42 
 
In cell division DNA-strands condensate into chromosomes that line up at the center of the cell 
(metaphase). The microtubules form nuclear spindle that pulls the chromosomes apart, splitting 
them into two when the cell divides (anaphase). Drugs binding to the vinca domain prevent cell 
division by binding to the nuclear spindle (microtubules) and stopping their normal functioning.15 
Thus, the cell is forced to remain in the metaphase, never completing the cell division; this 
eventually induces apoptosis.  
 
The drugs of this study, MMAE and MMAF, belong to the vinca domain binding mitosis-inhibiting 
family of molecules.12, 13  The vinca domain is located between αβ-tubulin dimers so that a vinca 
domain binding molecule has interactions with both the β1- and the α2-subunits (Figure 4). The 
auristatins bind to the vinca domain from the N-terminal end of the structure while the rest of the 
long structure fits to the inter-dimer interface and the hydrophobic pockets.12 MMAE and MMAF 
are structurally very similar, but MMAFs higher affinity to tubulin is most likely due to the extra 
interaction of MMAF carboxylic acid group with β1-tubulin.12 
 
When a molecule binds to the vinca domain it changes the lateral interaction between the tubulin 
dimers.43, 44 When MMAE binds to tubulin, the tubulin subunits bend and twist slightly.13 The 
longitudinal interaction is weaker and the position of the tubulin dimers with each other is different 
9 
 
than when microtubules polymerize in the absence of the drug. Thus, the microtubule does not 
polymerize to a straight structure, but to a curved one instead43, 44 and the normal functioning of 
the microtubule is prevented. At high concentrations vinca domain binding drugs cause 
microtubule depolymerization, since the interaction surface between the tubulin dimers is smaller 
still.15, 44 The vinca domain binding molecules used as medicine prevent mitosis in small, 
nanomolar concentrations that do not induce depolymerization15 and the drug effect is due to 
prevention of mitosis.   
 
Molecules that bind to the vinca domain prevent the normal functions of microtubules also by 
preventing the nucleotide exchange12, 14, 45 and hydrolysis14, 43, 45. GTP plays an important role in 
the dynamic instability of microtubules. After microtubule depolymerization the GDP in a tubulin 
dimer has to change into GTP in order for an αβ-tubulin dimer to bind to a new microtubule again.6 
The C-terminus of tubulin-bound MMAE and MMAF is located at the vicinity of the GTP (Figure 
4), preventing nucleotide exchange.12  
 
2.2 Modifying the Auristatins 
 
Both monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) have been 
developed from dolastatin 10, a cytotoxic pentapeptide that was first isolated from the sea hare 
Dolabella auricularia in 1987.46 Dolastatin 10 binds to microtubules at the vinca domain (Figure 
4) and prevents mitosis by preventing the normal function of microtubules.14, 45 Dolastatin 10 
consists of five amino acids; dolavaline (Dov), valine (Val), dolaisoleuine (Dil), dolaproine (Dap) 
and dolaphenine (Doe). Dolastatin 10 prevents mitosis in vitro and advanced to clinical trials, but 
no successful results have been reported.47 Thus it was apparent that the structure of dolastatin 10 
needed to be modified. 
 
Structure-activity relationship (SAR) studies for dolastatin 10 by Bai et. al.48, 49 revealed that 
configuration changes should not be made at the first three amino acids and that the new analogues 
should focus on finding alternative amino acid residues to replace Dap and/or Doe. Dolastatin 10 
was exceptionally cytotoxic in vitro, so it was suggested that even if the modifications reduce the 
cytotoxicity, they should still be considered, since dolastatin 10 might be too toxic for use in 
patients. A less toxic, but more easily synthesized alternative for Doe should also be considered 
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for further development, since preparation of dolaphenine was the most difficult and expensive 
step of the synthesis. This led to the development of Auristatin E, where Doe has been replaced 
with norephedrine.50 
 
 
Figure 4. MMAE binding site is located at the interface of two αβ-tubulin dimers. MMAE has been 
circled with orange, the arrow points to GTP. PDB ID: 5IYZ12 
 
Miyazaki et. al.51 made several structural analogs of dolastatin 10, performing modifications in all 
the five amino acids to see how they affected activity (SAR presented in Figure 5). Removal of the 
second amino acid, valine, lead to loss of activity, meaning that all five amino acids were needed 
for activity. They also noted that removal of one methyl group from N-terminus did not change the 
activity. One of the analogs had higher antitumor activity than dolastatin 10, and it was developed 
further and later named soblidotin (TZT-1027).52, 53 In soblidotin the dolaphenine moiety thiazole 
ring is replaced by a hydrogen. It advanced to clinical trials, but with no successful results.47 
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Figure 5. Dolastatin 10 SAR adapted from Miyazaki et al.51 Places where structural changes have 
been made are circled.  
 
Auristatin E was further developed by Doronina et al.39 to be used as and ADC. For the drug to be 
used as a warhead molecule, it needs to be attached to an antibody. For this, they removed one of 
the methyl groups at the N-terminus end Dov residue, forming monomethyl auristatin E.39, 54, 55 
With ADCs in mind, monomethyl auristatin F was developed a few years later with the goal of 
developing a molecule that would be even more active once released to the target cell.40  
 
Thus, like dolastatin 10, MMAE and MMAF are composed of five different amino acids (Figure 
6). MMAE consists of norephedrine, dolaproine, dolaisoleuine, valine and monomethyl valine. 
MMAF has otherwise similar structure, but the norephedrine moiety is replaced by phenylalanine. 
In other words, MMAE has a hydroxyl group whereas MMAF has a carboxylic acid group. Due to 
this structural difference MMAE is a neutral molecule in physiological pH while MMAF is a 
negatively charged species.12, 40, 56  Doronina et al.40  also synthesized a neutral MMAF derivative, 
MMAF-OMe, which was highly toxic, since as a neutral molecule it can enter cells more easily 
than MMAF. However, instead of MMAF-OMe, MMAF has been developed into an ADC since it 
is effective once it reaches the target, but less toxic as a free agent. 
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Figure 6. MMAE (above) consist of monomethyl valine (MeVal), valine (Val), dolaisoleiune (Dil), 
dolaproine (Dap) and norephedrine (PPA). MMAF (below) has otherwise similar structure, but 
norephedrine is replaced by phenylalanine (Phe). The black circle shows the site of modification. 
Both auristatins are shown in their cis-conformer. 
 
Both MMAE and MMAF exist as two distinct, nearly isoenergetic conformers in solution, as 
rotation around the amide bond between dolaproine and dolaisoleuine is partially hindered.17 The 
extended structure of the trans-conformer resembles the tubulin-bound form of the molecule while 
the cis-conformer is a more contorted compact structure (Figure 7).12, 13, 17 
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Figure 7. A 3D representation of the cis- and trans-forms of MMAE. The green discs show the 
peptide bond that needs to be rotate for one conformer to change to the other. The coloring shows 
the division for intramolecular interactions analysis, MeVal (green), Val (purple), Dil (light blue), 
Dap (red) and PPA (divided into yellow link part and grey phenyl part). Green ball shows the site 
of modification. Figure from 57. 
 
The effects of antibody-bound and free MMAE and MMAF on certain CD30-positive cell lines in 
vitro have been studied.40, 58 The free MMAE was found to be significantly (50- to 200-fold) more 
effective than free MMAF. This is because MMAF is charged and thus cannot freely pass through 
the cell membrane, while the neutral MMAE is able to do so. While free MMAE is more effective 
than free MMAF, the antibody-bound MMAF is significantly more potent than the antibody-bound 
MMAE.40, 58 MMAF binds five times more strongly to tubulin than MMAE, which might explain 
this difference.12 An important point to note is that neutral auristatin derivatives like MMAE and 
MMAF-OMe are not cell specific and would enter and kill any given cell. In order to use these 
cytotoxic agents as cancer drugs they need to be attached to an antibody that targets certain cells.  
 
Antibody-bound MMAF is more potent and less toxic than similar MMAE, likely since after 
reaching the target cell the MMAF stays there.39, 40, 58 Part of the potency of the MMAE containing 
ADC brentuximab vedotin might be explained by the so-called bystander killing effect.10 The free 
MMAE exits the target cell and enters a neighboring cell causing damage. Adcetris is used in the 
treatment of CD30-positive Hodgkin lymphoma where the healthy cells in the microenvironment 
of the cancer cells support their proliferation. Destroying such neighboring cells may help kill the 
cancer cells faster. MMAE’s ability to exit the target cell may be a benefit in treatment of such 
cancers, but it also increases the risk of side effects (overall toxicity).  
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As noted before, the three parts of an ADC, the warhead (cytotoxic agent), the antibody, and the 
linker, all affect the properties of the ADC.36, 38-40 In the development of MMAE ADC Doronina 
et al.39 tested valine-citrulline (Val-Cit) and phenylalanine-lysine linkers and noted that MMAE 
attached to the antibody with Val-Cit linker was more effective against the cancer cell line. 
Brentuximab vedotin uses the cathepsin B cleavable valine-citrulline (Val-Cit) linker.10 The 
optimal drug loading for MMAE was found to be four drug molecules per antibody.59 Eight MMAE 
molecules per antibody was as effective as, but not more effective than, four MMAE molecules 
per antibody. With eight MMAE molecules per antibody, drug clearance was higher, that is, the 
drug exited the body faster and the tumor exposure to MMAE was less compared to drug loading 
of four. With only two MMAEs per antibody, the dose needed to be doubled to have the same 
effect as four. Thus, it was concluded that four MMAE molecules per antibody was the optimal 
drug loading.  
 
Similarly, different linkers and drug loadings were tested for MMAF.40 MMAF attached to an 
antibody with maleimidocaproyl linker (mafodotin) with four MMAF molecules per antibody was 
found to be effective in in vitro assay and has been developed further. Also, other antibodies25, 
linkers60, 61 and drug delivery systems62 have been used and other modifications to the auristatins 
have been made. Some of the modifications include enhancing the lipophilicity of the auristatin63, 
attachment of a phosphate64, pyrrolidine ring modifications65, N-terminal end modifications66 and 
others66, 67. 
 
3 Motivation 
 
The starting point of this study is the observation by Johansson et al.17 that up to 60 % of both 
MMAE and MMAF exist in the biologically inactive cis-conformation in solution. In other words, 
when the drug is released to the cell, only about half of the drug molecules are in the active trans-
conformer and able to bind to the tubulins and prevent their normal function. The cis-conformer 
can change to the trans-conformer (and the other way around) by rotation of an amide bond. The 
calculated energy barrier for rotation is quite high (~100 kJ/mol), and it is estimated that the 
conversion from one conformer to another takes several hours in body temperature. 
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In general, cancer drugs cause several unwanted side effects. A common side-effect of mitosis 
inhibitors is peripheral neuropathy.8-11 This is most likely caused by their mode of action: their 
effect on microtubules. The signal molecules of the cell move on the surface of the microtubules. 
A typical nerve cell consists of dendrites, the cell body (soma) and an axon.6, 68 The somas of 
peripheral nerves are located in the spine and their axons may extend over a meter in length. Most 
signaling molecules are produced at the soma and are transported to the axon terminal by motor 
proteins that run along microtubules. If the microtubules are damaged, the transportation of signal 
molecules is disturbed, and this is observed as abnormal sensations. Therefore, damage to 
microtubules is observed as the symptoms of peripheral neuropathy, which include hypoesthesia 
(impaired sensitivity), hyperesthesia (elevated sensitivity), paresthesia (abnormal sensations), 
discomfort, a burning sensation, neuropathic pain or weakness.18 The symptoms of peripheral 
neuropathy associated with Adcetris are due to cumulative exposure to the drug and the symptoms 
usually improve or resolve after the end of treatment.18, 41 Similarly, studies with polatuzumab 
vedotin imply that higher doses and longer treatment times lead to increased occurrence and more 
severe peripheral neuropathy.11, 69 
 
It is possible that some of the side-effects caused by the auristatins arise from them leaving the 
target cell in their inactive forms, and then entering into a healthy cell where they isomerize into 
the active trans-conformer. Inside the cell the molecule binds to its target, causing damage to the 
healthy cell. With a reduced amount of the inactive cis-conformer the likelihood of the drug exiting 
the target cell in its inactive cis-form, diffusing into the healthy tissue and changing to the active 
conformer is reduced. Also, the drug would not be metabolized in its inactive form before it gets 
to bind to the target. A smaller drug dosage would be safer in general also because a lesser amount 
of the drug would be in blood circulation. 
 
We note that the issue of the two isomers could be remedied also by modifying the rotational barrier 
of the bond rotation that connects the two isomers. With a significantly lower barrier, the cis-isomer 
would quickly isomerize to the active trans-form while still inside the cancer cell. With a 
sufficiently high barrier, the transformation of cis to trans would be effectively prevented. 
Modifying the rotational barrier of a peptide bond would, however, be highly challenging. Another 
approach would be to lock the molecule to the trans-form by, for example, addition of a heteroatom 
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ring that contains the amide bond in the desired conformation. However, this approach would make 
the molecule bulkier, which might affect its binding, and more lipophilic, which would make the 
already poorly soluble17 auristatin even less soluble. 
 
Thus, the goal of this study was to modify the structure of MMAE and MMAF so that the 
biologically active trans-conformer would become the dominant conformer. This could be 
achieved by either making the cis-conformer less stable or the trans-conformer more stable (or a 
combination of the two approaches). If the cis/trans-equilibrium was shifted more completely 
toward the trans-conformer, more of the drug would be in the active form when reaching the cancer 
cell. This would increase the potency of the drug, meaning that a lower dose of the auristatin would 
be needed. Also, the safety of the drug could be improved, both directly due to a lower drug dosage 
and indirectly since the risk of the inactive conformer leaving the target cell and entering a healthy 
cell would be decreased.  
 
4 Computational Methods 
 
The aim of drug discovery is to find new active drug molecules. Computational methods are applied 
at several different stages of a drug discovery process.70, 71 For example, they can be used to screen 
large libraries of molecules to identify hits (molecules that bind to the target)70-72 as well as in 
designing completely new compounds or in optimizing the properties of the compounds.70  
Screening can be done experimentally, but it’s slow, laborious and costly and the amount of active 
molecules found per molecules tested (the hit rate) is quite low.72  In virtual screening (VS), 
computational methods are used to identify active molecules. VS usually has better hit rate, is faster 
and less costly. Several different VS strategies exist. Here we will concentrate on small molecule 
docking since it was used in this work. 
 
Docking is a process where a small molecule (ligand) is placed to a binding pocket of a 
macromolecule (a protein, often called a receptor) and the interactions between the small molecule 
and the macromolecule are estimated using a scoring function.71, 72  The binding pocket can either 
be pre-determined or located during the docking process. Pre-determined binding pockets are 
usually based on X-ray crystal structures of a known ligand to the protein. In general docking is 
divided into two parts, conformational search (binding pose generation) and scoring part (binding 
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energy evaluation). Binding poses can be predicted relatively accurately but scoring and ranking 
them remains a challenge.73 Several different docking programs exist, with different strengths and 
weaknesses. It can be concluded that the choice of the best suited docking program depends on the 
application.71, 73, 74  
 
One of the challenges for docking pose prediction is the choice of the protein model, as crystal 
structures often show only one of the many conformations the protein may have.73 Dynamics are 
an important part of ligand binding in reality, as ligand binding itself may impose conformational 
change.70, 72 Some docking programs are able to take protein and/or ligand flexibility into account, 
while some keep both the ligand and the protein rigid.  
 
Ligand-protein interactions are evaluated by a scoring function.70, 71, 75 Based on the score, the 
ligands are ranked in order of predicted biological activity. Scoring functions are usually divided 
to three different categories; force-field, empirical or knowledge-based scoring functions.71, 72 Fast 
evaluation of binding energy requires some approximations from the scoring function. For 
example, many scoring functions ignore entropic changes, and solvation effects are often either 
crudely approximated or ignored.71 More accurate quantum chemical methods have been used in 
several different applications to increase the accuracy of the binging energy prediction.76 The main 
problem of using more accurate, and therefore computationally more demanding methods, is that 
the cost of the calculations limits both the amount of conformational sampling that can be 
performed as well as the number of candidate molecules to be tested.74, 76     
 
In this work, computational methods that are based on quantum mechanics and quantum chemistry 
were used to calculate energies of the virtually modified auristatin structures. Since we aimed to 
improve the cis/trans-conformational equilibrium the focus was in the relative stability of the 
conformers for each molecule. We also used docking to analyze the change in protein-ligand 
binding the modification might cause.  
 
4.1 Theory of Computational Methods 
 
Quantum chemical (QM) computational methods aim to work out the energy and other properties 
of a molecular system by finding a solution to the Schrödinger equation. In principle, if we 
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disregard relativistic effects, the exact solution to the equation (Equation (1)) contains all the 
physical information about the system.77 
 ?̂?Ψ = EΨ , (1) 
?̂? is the Hamiltonian operator, Ψ is the wave function of the system and E is the energy. The 
Hamiltonian operator is composed of terms (operators) for the kinetic and potential energy. The 
kinetic energy term consists of kinetic energy of nuclei and electrons, while the potential energy 
term contains electron-electron, nucleus-nucleus and nucleus-electron interaction terms. The 
Schrödinger equation is usually solved to find a wave function that gives the lowest energy value, 
denoted the ground state wave-function/energy.  
 
As the Schrödinger equation cannot be solved exactly (for systems with more than two particles), 
it needs to be solved approximately.77 The Hartree-Fock (HF) approximation78, 79 is usually the 
starting point for the ab initio wave-function methods.80 Ab initio is Latin and means “from the 
beginning”; in this context it means that the solutions are generated only with reference to physical 
constants and without reference to, for example, experimental data. In HF the wave function is 
represented by several one electron wave functions (aka orbitals), which only indirectly interact 
with each other. Even if a HF calculation recovers about 99% of the total energy, it is not accurate 
enough for chemical problems; 1% of the total energy of a molecular system is chemically a huge 
number. In the HF model the electron exists in an average potential field created by all the other 
electrons. Thus, HF does not take individual electron-electron interactions into account. Electrons 
repel each other, and as they move through space, they change their path to avoid each other.77, 81 
This in turn affects the movement of all the other electrons; the movements of electrons correlate. 
By avoiding each other the electrons minimize repulsion and the overall energy is lowered. This 
energy lowering, which HF ignores, is called the correlation energy.  
 
To obtain chemically relevant results, more accurate computational methods than HF have to be 
used.77 In perturbation theory, such as Møller-Plesset (MP)82 theory, the energy consists of the HF 
ground state energy and a small perturbation that accounts for the electron correlation. In coupled 
cluster (CC)83, 84 theory a more accurate wave function is constructed by combining the ground 
state HF configuration with configurations constructed by exciting electrons from the reference 
(HF) orbitals to virtual orbitals. These are all wave-function methods.  
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Another approach is density functional theory (DFT) where the energy is calculated from the 
electron density. Most of the energy is calculated exactly and a small exchange-correlation energy 
is approximated using a functional. Figure 8 shows the computational methods in relation to each 
other. 
 
 
Figure 8. The computational methods used in this work are shown as a hierarchical flowchart in 
relation to each other. Ab initio methods can be divided into HF and post-HF methods (that include 
MP2 and CC). DFT functionals can be grouped into categories shown here and explained further 
in section 4.5.  
 
4.2 Hartree-Fock Theory, HF 
 
In Hartree-Fock78, 79 theory the energy is calculated using a Fock operator that operates over one-
electron wave functions (that consist of spatial and spin parts).77  The one electron wave function 
orbitals (spatial parts) are expressed as trial functions. The Fock operator consist of the electron 
kinetic-energy operator, nucleus-electron attraction and average electron-electron repulsion terms. 
Each electron exists in an average potential field created by all the other electrons (and all the 
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nuclei). The calculation starts with a set of trial orbitals. These are optimized during the calculation, 
which is iterated until the orbitals and energy result do not improve anymore, that is, until 
convergence has been reached. This is called the Self-Consisted Field (SCF) method.85  
 
Since the energy values are so big, even seemingly small 1% is chemically important. For example, 
the total energy value for cis-MMAE calculated at CCSD(T)-level is 6 101 793 kJ/mol, meaning 
that 1% of this is 61 018 kJ/mol. In comparison, the dissociation energy for a single carbon-carbon 
(C-C) bond is 605 kJ/mol.86 This 1 % comes from electron correlation and taking it into account 
will lower the energy. The total energy for cis-MMAE at HF level is 6 073 115 kJ/mol, recovering 
99.5 % of the total energy. HF has formal scaling of N3.77  
 
4.3 Second Order Møller-Plesset Theory, MP2 
 
In Møller-Plesset (MP) perturbation theory, the energy consists of the ground state HF energy and 
an energy term that arises from perturbations (Equation (2)).82 Second order MP (MP2)87 is among 
the cheapest wave function methods that take electron correlation into account, typically returning 
80-90% of the correlation energy.77  
 EMP2 = EHF + λE
′  (2) 
Electrons with parallel and antiparallel spins interact differently with each other, giving different 
contributions to the correlation energy. The regular MP2 theory overestimates contributions from 
the interaction between electrons of parallel spin, and underestimates the correlation energy 
between electrons of opposite spin.88, 89 In Spin-Component Scaled MP2 (SCS-MP2) the spin 
contributions are scaled so that the short-ranged, opposite-spin electron correlation is enhanced, 
and the long-range, same-spin electron correlation energy is scaled down (Equation (3)).  This 
simple correction usually gives significantly improved results. 
 ESCS−MP2 =
1
3
E↑↑ +
6
5
E↑↓  (3) 
The total energy value for cis-MMAE calculated at MP2-level is 6 099 009 kJ/mol. For cis-MMAE 
MP2 recovers 99.95 % of the total energy. MP2 scales as N5.77 
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4.4 Coupled Cluster Theory, CCSD(T) 
 
In coupled cluster (CC) theory the description of the wave function is improved by constructing it 
as a superposition of the ground state Hartree-Fock wave-function, and wave-functions constructed 
by virtually exciting electrons from the occupied HF orbitals to virtual ones.77, 83, 84 In the CCSD 
method, configurations that arise from single and disconnected double electron excitations are 
accounted for. In the CCSD(T) method, the simultaneous excitation of three electrons are also 
included, but only perturbatively. This leads to scaling of N7.77 Thus, if the system size grows 10-
fold, the calculation would take 107 times more time to compute. Coupled cluster theory accounts 
for even more electron correlation than MP2, recovering 99.99% of the total energy at CCSD(T) 
level.77 Due to this high accuracy, CCSD(T) is often referred to as the gold standard of quantum 
chemical methods.90, 91 
 
4.4.1 DLPNO-CCSD(T) 
 
In the domain based local pair natural orbital coupled cluster method, DLPNO-CC, the 
computational burden of accurately computing the electron-electron interactions is reduced by two 
approaches: localizing the molecular orbitals and pre-screening the important energy contributions 
at a lower level (MP2).92, 93  
 
The standard canonical orbitals extend over the whole molecule and are very diffuse. Because of 
this, all possible orbital pairs are close enough to each other to interact. Thus, in order to calculate 
the energy at the accurate CCSD(T) level, interactions between all possible orbitals would need to 
be calculated. In the DLPNO methods, the orbitals are first localized on certain atoms or atom 
groups, in other words divided into domains. Localization is possible, as the total wavefunction 
does not change even if the orbitals are modified by a unitary transformation. By finding an 
appropriate unitary transformation that creates a new set of orbitals as linear combinations of the 
canonical orbitals, the spatial extent of the orbitals can often be reduced. A common scheme, used 
also in this work, is the Foster–Boys localization method.94, 95  
 
The localized orbitals are used to calculate the interaction energies at a lower level, often MP2. If 
the MP2 interaction energy exceeds a preset value, the energy is calculated at the more accurate 
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CCSD(T) level. Otherwise, the specific pair-interaction energy is approximated at the lower level 
of theory. Orbital localization reduces the amount of interacting orbital pairs, especially for bigger 
molecules, since most of the localized orbitals are spatially so far from each other that their 
interaction energy does not contribute significantly to the total energy. This together with a proper 
implementation has made DLPNO-CCSD(T) a linearly scaling method,96  whereas regular 
CCSD(T) scales as N7.77 For small systems, the DLPNO-CCSD(T) scaling is close to standard, 
canonical CC, since all of the electrons are close enough to interact and thus all the interaction 
energies between orbitals need to be calculated accurately to obtain CC level accuracy. Large 
molecules, like MMAE and MMAF, which are far too big for regular CCSD(T) calculations, 
benefit greatly from the DLPNO scheme. Reliable coupled-cluster level results can be obtained by 
employing DLPNO-CCSD(T). 
 
4.5 Density Functional Theory, DFT-D3 
 
Hohenberg and Kohn have shown that in the absence of a magnetic field the (ground state) electron 
density completely and uniquely defines the energy and all other observables of a molecule97; 
integration over the electron density gives the number of electrons98. HF, the simplest wavefunction 
theory, is a 3N dimensional problem, with N the number of electrons, whereas the density depends 
only on the three variables of 3D space. Thus, in principle, density functional theory (DFT) is a 
simpler method than the wave function methods. However, in order to describe the kinetic energy 
of the electrons accurately, using just the total electron density is highly challenging. Therefore, 
orbitals are usually used. This Kohn-Sham approach makes also DFT a 3N dimensional problem.77, 
99  
 
In DFT most of the energy is calculated exactly and only a small exchange-correlation energy is 
approximated. If the form of the functional that maps electron density to energy was known, DFT 
calculations would give exact results. Unfortunately, this is not the case. Instead, several 
approximated functionals have been constructed.100  
 
The energy expression contains terms for the kinetic energy (T), Coulomb repulsion between 
electrons (J), and nucleus-electron attraction (Vne), as well as the approximate part of DFT, the 
exchange-correlation energy (EXC) (Equation (4)).
77, 100 
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 EDFT = T + Vne + J + EXC  (4) 
The exchange-correlation term attempts to estimate the exchange and correlation energies and is 
often constructed as a sum of exchange and correlation energy terms.77, 100 Several different 
functionals exist100 and they can be roughly categorized on how much of the information contained 
in the electron density they utilize. Perdew introduced Jacob’s ladder of DFT for visualizing the 
sequence.81 The higher we go on Jacob’s ladder, the more complex electron density derivatives are 
included: 1) local spin densities (local spin density approximation, LSDA) 2) gradients of the local 
spin densities (generalized gradient approximation, GGA) 3) orbital kinetic energy density (meta-
GGA) 4) exact exchange energy density from occupied orbitals (hyper-GGA), and 5) information 
from unoccupied orbitals.81, 101, 102  
 
In addition to the classification by Jacob’s DFT ladder, density functionals can also be classified 
by how many ingredients from wave-function theory are included. The pure functionals have no 
portion of wave-function theory within their definition, while hybrid functionals usually contain a 
fraction of Hartree–Fock type exchange energy. Double hybrid functionals also include a MP2-like 
term.103 The functional used in this work, hybrid Tao−Perdew−Staroverov−Scuseria (TPSSh)104, 
can be considered to stand somewhere between the third and fourth rungs of the ladder.77 TPSS is 
a non-empirical, purely meta-GGA density functional, while its hybrid form TPSSh contains 10% 
of Hartree-Fock-like exchange (Equation (5)).104  
 EXC
TPSSh = 0.10 ∗ EX
HF + 0.90 ∗ EX
TPSS + EC
TPSS  (5) 
 
Dispersion energy is a challenge for DFT. Dispersion is a long-range phenomenon with a very 
small effect on the electron density. As local DFT-functionals take only the local electron density 
(or its gradient) as input they are not able to capture the physics of dispersion.102, 105, 106 In 
Grimme’s107, 108 DFT-D3 approximation, the dispersion energy is simply added as empirical atom-
pair wise specific dispersion contributions (Equation (6)). As the dispersion terms depend inversely 
on the distance between the atom pairs (as 1/Rij6), they have to be damped at short interatomic 
distances in order to avoid infinite attraction. In this work, we have used the Becke–Johnson type 
damping.109   
 EDFT−D3 = EDFT + ED3 (6) 
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4.6 Symmetry Adapted Perturbation Theory 
 
Symmetry adapted perturbation theory (SAPT) is a quantum chemical method that can be used to 
calculate interaction energies.110-112 Here we used F/I-SAPT0 (F for functional groups and I for 
intramolecular interaction energy between two moieties in the presence of a third moiety) to 
analyze the intramolecular interaction energies. For the analysis, the molecule is divided into 
fragments and the interaction energy between the different fragments is calculated. For MMAE the 
partitioning is shown in Figure 7. SAPT natively provides an energy decomposition analysis. In 
SAPT the energy is divided into four main parts; electrostatic, dispersion, exchange and induction 
energy (Equation (7)).    
 ESAPT =  Eelectrostatic + Edispersion + Eexchange + Einduction (7) 
The division to the four energy components is done for conceptual reasons. It should be kept in 
mind that only the total energy is an actual physical quantity. Thus, the division into energy 
components could be done in any arbitrary way. The division helps in understanding where the 
different interaction energy components come from, but their exact physical meaning can be 
debated. The electrostatic energy comes from the classical electron-electron and nucleus-nucleus 
repulsion and electron-nucleus attraction. The exchange energy arises from the quantum 
mechanical electron-electron repulsion, with origins in the Pauli principle; it can be seen as a steric 
repulsion term. The dispersion energy arises from momentary changes in the electron density that 
induces change in the charge distribution at another point in space, which leads to attraction. The 
induction energy comes from the interaction of the permanent multipole moments of one fragment 
and the induced multipole moments on the other fragment. 
 
4.7 Basis Sets 
 
In molecular quantum chemistry, the one-electron wave-functions (the molecular orbitals), are 
usually expressed as a linear combination of a certain type of mathematical functions. These 
functions are called basis functions, and they resemble atomic orbitals in form. Gaussian-Type 
Orbitals (GTOs) are often used, since they are computationally efficient. The wave function or 
electron density can be described by combining basis functions. The more basis functions are used, 
the more accurate the results are. In principle, a completely accurate calculation of the energy 
requires an infinite amount of basis functions.77  However, more basis functions also lead to 
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computationally more expensive calculations. Thus, a compromise between accuracy and 
efficiency needs to be made. Different methods have different requirements for the basis set quality. 
It is thus important to choose an appropriate basis set for the task at hand.  
 
Several different basis set families have been developed, and they follow a certain naming system.77 
In general, basis sets are named by how many basis functions they contain as XZ, where X is the 
cardinal number S, D, T, Q, etc. S stands for single (the minimum basis), D for double, T for triple 
etc. meaning that a DZ basis set has double the amount of basis functions compared to SZ. Since 
mainly valence electrons participate in chemical reactions, it is not necessary to describe the core 
electrons with more basis functions than minimum, and therefore most basis sets only increase the 
number of valence functions when increasing the basis set size. Polarization functions are important 
for describing bonding, as the electron density is significantly deformed from that of separate 
atoms. S-orbitals are polarized with p-orbitals and p-orbitals are polarized with d-orbitals and so 
on. For Karlsruhe-type basis sets polarization is marked as P.113 Diffuse functions, functions that 
extend far from the nuclei, further improve the representation of the molecular orbitals.114  They 
are important for describing, for example, anions, polarizability, and dispersion interactions 
properly. In this work we have used the double polarized (PP) Karlsruhe basis sets, augmented 
with diffuse functions (D), e.g. def-TZVPPD. 
 
4.8 Non-Covalent Interactions Analysis 
 
Noncovalent interactions were plotted using the NCIPLOT program.115 It uses information 
contained in the electron density to calculate and color regions in space where there are non-
covalent interactions between atoms.116 Electron density (𝜌) and reduced density gradient are 
calculated at DFT level and non-covalent interactions are recognized as low-gradient, low-density 
regions in space. The type of the non-covalent interaction comes from the sign of the second 
eigenvalue of the second derivative of the electron density (∇2𝜌)  and the strength of the interaction 
comes from the density on the non-covalent interaction surface. Thus, dispersion interactions and 
hydrogen bonds can be visualized easily. An example of the results of the NCI analysis is shown 
in Figure 10 in section 7.2. 
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4.9 AutoDock 
 
AutoDock117, 118 is a widely used docking program: a Web of Science search from all databases 
with keyword “AutoDock” provides 2,573 hits by September 2019. AutoDock uses a grid-based 
method to rapidly evaluate binding energies of trial conformations.118 The binding site location and 
size can be chosen by the user, but it is also possible to search for a binding site on the 
macromolecule, if a grid with larger spacing is used (although this decreases accuracy).119 First, a 
grid of pairwise interaction energies between the macromolecule and ligand is calculated so that it 
can be used later during docking as a look-up table.75 AutoDock incorporates some ligand and 
protein flexibility.118 The scoring function used in AutoDock is force-field based and consist of 
terms for van der Waals interactions, hydrogen bonds, electrostatic interactions, torsional degrees 
of freedom, and solvation.71, 75, 118 
 
During docking, the program places the ligand in the binding site, evaluates its interaction energy, 
goes through the conformational space by changing the torsional angles and evaluating binding 
energies of each conformation.75, 119  The produced conformations are clustered together, a default 
root-mean-square deviation (RMSD) value for a cluster is 2 Å (for AutoDock4118). The clusters are 
ranked based on their binding energy. 
 
5 Experiment 
 
We aimed for a relatively simple and easy modification of auristatins that would still affect the 
cis/trans-equilibrium. Initial atomic coordinates for the MMAE and MMAF structures were taken 
from Johansson et al.17 and the para-position of the benzene ring of the structures was halogenated 
with fluorine and chlorine. Other modifications were also tested, but none of them were equally 
promising. Halogenation of drug molecules has been a drug design trend.120-122 At first it was used 
to improve the lipophilic properties and only later to enhance the receptor binding affinity as well 
as to enhance bioavailability by avoiding certain metabolic pathways.123, 124 Changing the phenyl 
ring para-position hydrogen to a halogen is a relatively easy modification both computationally 
and in the synthesis of the molecule.  
 
In practice the experiment was done by optimizing the geometries of the modified auristatins at 
DFT level to see the effect of the modification on the relative stability of each conformer. The 
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results were corroborated by calculations at MP2 and CC level. The effects of the modification on 
the intramolecular interaction energies were analyzed using SAPT and visualized using NCIPLOT. 
Since a drug needs to bind to its target in order to be effective, we performed docking studies using 
AutoDock to see if the modification would affect binding. 
 
6 Methods 
 
The original MMAE and MMAF structures were taken from Johansson et al.17 The desired 
modification was done, and the geometry was optimized at DFT-level, using TPSSh104 functional 
with Grimme’s D3(BJ)107-109 dispersion correction with Becke-Johnson damping. The doubly 
polarized triple-zeta def2-TZVPP basis set113 was used, and integration performed with the fine 
“m4” grip.125  Solvation effects were modeled using COSMO126 continuum solvation model, with 
the dielectric constant ε set to 32.6, simulating a methanol environment, or alternatively, the 
dielectricity inside a cell127, 128. For MMAF, a structure where the carboxyl acid had turned 
compared to the structure used in Ref. 17 was found to be slightly lower in energy, and thus used 
as a starting point for the modified MMAF structures. MMAE and MMAF original molecules exist 
as two major conformations in solution,17 and it was assumed that only two conformations are 
relevant also in the case of the halogenated auristatins. 
 
The results at DFT-level were corroborated using wave-function based methods. Spin-Component 
Scaled second order Møller-Plesset theory82, 87-89 was used in connection with the doubly polarized 
quadruple-zeta def2-QZVPPD basis set, augmented with diffuse functions114. DLPNO-CCSD(T)92, 
93, 96 was used to calculate the final electronic energies. The two-point basis-set extrapolation 
formula by Halkier et al.129 was used to extrapolate toward the complete basis set limit from the 
def2-TZVPPD and def2-QZVPPD basis sets.113, 114 The DLPNO-CCSD(T) calculations were 
performed with both NormalPNO and TightPNO settings90 using def2-TZVPP and def2-QZVPP 
basis sets to compare the effect of the different setting. Solvation was accounted for by the 
COSMO126 model, simulating an aqueous environment, with ε = 78. 
 
Gibbs free energy at 310 K (body temperature) was estimated from harmonic vibrational 
frequencies, computed using analytical second derivatives.130, 131 For the vibrational frequencies, 
the geometries were re-optimized in gas phase at DFT/TPSSh level, using the polarized double-
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zeta/split valence def2-SVP basis set113 and the very fine “m5” integration grid.125 Vibrations below 
50 cm-1 were set to 50 cm-1. Intramolecular interactions were calculated using symmetry-adapted 
perturbation theory, F/I-SAPT0110-112, with the augmented double-zeta jun-cc-pVDZ basis set132 in 
gas phase. 
 
Docking was conducted using AutoDock version 4.2.6.117, 118 AutoDockTools version 1.5.6 was 
used to set up the calculations. The Tubulin-MMAE complex (PDB ID 5IYZ)12  was used as the 
protein model. The binding site is located at the interface of chains B and C. Therefore, the other 
chains, waters and the original ligand (ID 4Q5) were removed before docking. The original crystal-
structure ligand was used as the starting conformation, replacing the phenyl ring para-hydrogen 
with fluorine or chlorine for F-MMAE and Cl-MMAE, respectively. Standard Gasteiger charges133 
were used for the protein, and for the ligands, restrained electrostatic potential (RESP) charges134 
based on the TPSSh/def2-TZVPP electron density were computed. Ligand torsion angles were set 
to non-rotatable (inactive), except for the four bonds in the norephedrine moiety. AutoGrid was 
used to calculate a grid box of the size 40 x 60 x 40 points. The grid was centered at the original 
ligand position. Default values were used for the calculation. A total of 500 independent search 
runs, each with a maximum of 2.5 million energy evaluations, utilizing the Lamarckian genetic 
algorithm75, were done for each ligand; the lowest energy docking pose was located already after 
20 search runs in all cases. 
 
The DFT and MP2 calculations were done using TURBOMOLE version 7.1-7.4125, 135, 136, the 
coupled cluster calculations with Orca version 4.0.1.2137, RESP with NWChem version 6.8138, 
SAPT with PS4 version 1.1,139 and the noncovalent interaction analysis with NCIPLOT version 
3115. Jmol140 and VMD141 have been used for visualization. 
 
7 Results 
 
7.1 Isomer Energy Differences at Different Levels of Theory 
 
The initial DFT calculations gave promising results, showing that halogenation is able to shift the 
cis/trans-equilibrium more toward the trans-conformer compared to the original auristatins. We 
found that the halogenation of the benzene ring creates more favorable intramolecular interactions 
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in the trans-form, stabilizing it compared to the cis-form, thus shifting the cis/trans-equilibrium 
toward the trans-form. The origins of the stabilization are discussed in the next section. Here, we 
begin by comparing the results of the different levels of quantum chemical theory. 
 
 In order to corroborate the DFT-based results, wave-function based methods were used, namely 
second order perturbation theory (section 4.3) and coupled cluster theory (section 4.4). Table 1 
shows free energy difference (in kJ/mol) between the cis- and trans-conformations of the 
unmodified MMAE and MMAF molecules calculated with different computational methods; 
experimental values are included for comparison. Gibb’s free energy ∆G is calculated at 310 K to 
model body temperature.  
 
At DFT level the cis/trans-equilibrium is shifted too much toward the cis-conformer compared to 
experiment. This is either due to overestimation of the stability of the cis-conformer, 
underestimation of the stability of trans-conformer or a combination of both. This is an example 
where the computationally relatively cheap DFT method fails to be sufficiently accurate. The origin 
of the failure might lie in modeling of the intramolecular dispersion interactions, which have been 
found to be important in the case of large hydrocarbon molecules.105, 106 
 
Values computed with MP2 and CCSD(T), on the other hand, agree well with the experimental 
results, being within 1 kJ/mol from the experimental values. These correlated wave-function 
methods take dispersion interactions into account natively. They are more expensive, but they also 
agree better with experimental values.  
 
Table 1. Free energy difference, ∆G(310K), between the cis- and trans-conformations of the 
original MMAE and MMAF molecules calculated at different computational levels, as well as the 
experimental values. Energy values are in kJ/mol and a negative value means that the cis-conformer 
is lower in energy.  
  
DFT/TPSSh-
D3(BJ) 
SCS-MP2 
DLPNO-
CCSD(T) 
NormalPNO 
Experimental17  
MMAE -7.3 -1.7 -1.3 -0.9 
MMAF -6.0 +0.1 +0.2 -0.5 
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Similar trends between the results at different computational levels can be seen for the halogenated 
structures. The energy differences (in kJ/mol) between the cis- and trans-conformers for each 
molecule at different levels of theory are shown in Table 2. To enable a more direct comparison of 
the methods, the reported energies are (pure) electronic energies without additional corrections like 
solvation and thermal corrections. A negative value means that the cis-conformer is lower in 
energy.  
 
The data shows that halogenation of the molecules changes the cis/trans-equilibrium to favor the 
trans-conformer more than for the original molecules. At DFT level, the cis-conformer is favored 
less than before: the original MMAE cis/trans difference is -11.6 kJ/mol, whereas the difference is 
-2.9 kJ/mol for F-MMAE and -2.8 kJ/mol for Cl-MMAE. In other words, the relative energy 
change is 8.7-8.8 kJ/mol. In the case of MMAF the cis/trans energy difference goes from -10.6 
kJ/mol to -1.7 kJ/mol for F-MMAF (change of 8.9 kJ/mol) and to -0.0 kJ/mol for Cl-MMAF 
(change of 10.6 kJ/mol). 
 
Table 2. Comparison of gas phase electronic energies calculated with different computational 
methods. The energies are in kJ/mol, and the values are cis-trans energy difference, where a 
positive value means that the trans-conformer is lower in energy. 
 
DFT/TPSSh-D3(BJ) SCS-MP2 
DLPNO-CCSD(T) 
NormalPNO 
MMAE -11.6 -6.0 -5.6 
F-MMAE -2.9 +4.3 +4.6 
Cl-MMAE -2.8 +3.5 -2.2 
MMAF -10.6 -4.6 -4.4 
F-MMAF -1.7 +4.4 +7.0 
Cl-MMAF -0.0 +6.4 +5.2 
 
At the more accurate MP2 level the cis/trans-equilibrium favors the trans-conformer for all 
halogenated species (Table 2). For the original MMAE molecule, the cis-conformer is favored with 
the cis-trans energy difference being -6.0 kJ/mol. Halogenation changes this to favor the trans-
conformer with +4.3 kJ/mol for F-MMAE and +3.5 kJ/mol for Cl-MMAE (with change of 10.3 
and 9.5 kJ/mol respectively). For MMAF the results are similar, the energy difference goes from   
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-4.6 kJ/mol for original MMAF to +4.4 kJ/mol for F-MMAF and +6.4 kJ/mol for Cl-MMAF 
(change of 9.0 and 11.0 kJ/mol respectively). 
 
At coupled cluster level the trans-form is favored for F-MMAE, F-MMAF and Cl-MMAF (Table 
2). For MMAE the energy difference goes from -5.6 kJ/mol to +4.6 kJ/mol for F-MMAE (change 
of 10.2 kJ/mol).  For Cl-MMAE the cis-conformer is favored, but less than for the original 
molecule. The cis/trans energy difference is -2.2 kJ/mol for Cl-MMAE, with a change of only 3.4 
kJ/mol from original to chlorinated species. For MMAF the original favors cis-conformer with 
energy difference of -4.4 kJ/mol. This changes to favor the trans-conformer as +7.0 kJ/mol for F-
MMAF (change of 11.4 kJ/mol) and +5.2 kJ/mol for Cl-MMAF (change of 9.6 kJ/mol).  
 
Overall the cis/trans-equilibrium values obtained at MP2 and CC levels agree with each other and 
differ from the DFT estimates. The DFT results consistently predict the cis/trans-equilibrium to 
favor the cis-conformer more than the other methods do. However, the change in relative cis/trans-
equilibrium for each modified molecule in comparison to the original is about the same magnitude, 
regardless of the method used (9-11 kJ/mol, with the exception of Cl-MMAE at CC level). Thus, 
although absolute cis/trans energy difference at DFT level differs from the MP2 and CC results, 
the change in the relative energies is similar. This shows that the relative energies are not overly 
sensitive to the used method, most likely due to error cancellation. 
 
Table 3 shows the final energies and cis/trans-equilibriums calculated with DLPNO-CCSD(T) for 
the original and modified molecules. The middle column values include electronic energy, free 
energy (∆∆G) and solvation corrections (water as solvent). It can be noted that the simulated 
relative energies for MMAE and MMAF are the same whether the thermal corrections are 
calculated at 295 K or 310 K.57 The calculated energy differences for the original MMAE and 
MMAF agree well with the experimental values. From these final, best-estimate results it can be 
concluded that the cis/trans-equilibrium can indeed be improved by fluorination and chlorination 
at the para-position of the C-terminal phenyl group. The results for halogenated species show 
notable improvement in the cis/trans-equilibrium to favor the biologically active conformer. The 
change is significant for Cl-MMAF, F-MMAF, and F-MMAE, with the fraction of trans-conformer 
being 94, 90 and 79 %, respectively.  
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Table 3. Final cis/trans-equilibrium energies on DLPNO-CCSD(T) level, in kJ/mol. Solvation to 
water. (cis:trans ratio in parentheses) 
 MMAE  MMAF MMAE MMAF MMAE MMAF 
 ΔH, 310 K ΔG, 310 K ΔG, 295 K, exp17 
original -1.0 (59:41) +0.1 (49:51) -1.3 (62:38) +0.2 (48:52) -0.9 (59:41) -0.5 (55:45) 
para F +4.0 (17:83) +7.0 (6:94) +3.4 (21:79) +5.6 (10:90)   
para Cl +1.2 (39:61) +7.4 (5:95) +0.3 (47:53) +7.2 (6:94)   
 
We end this section with a discussion on computational efficiency. Figure 9 shows the formal 
scaling of the wave function methods. HF scales as N3, MP2 as N5 and CCSD(T) as N7. Using 
DLPNO-CC one can obtain CCSD(T) -level accuracy with linear scaling. Without the use of 
DLPNO such high accuracy results for MMAE and MMAF could not be obtained in reasonable 
time. DFT scales as N3 like HF, but the DFT results are accurate enough that they are applicable 
to chemical problems, unlike HF results. Thus, it can be noted that the advantage of DFT is that it 
is a cheap method with relatively accurate results. More precise wave function methods, like MP2 
and CCSD(T) used here give results that agree well with experimental values. The applicability of 
a certain methods depends on the problem.  
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Figure 9. Formal scaling of wave function methods. Hartree-Fock (HF) scales as N3 (red), Møller-
Plesset (MP2) scales as N5 (blue), canonical coupled cluster (CCSD(T)) scales as N7 (green) and 
domain based local pair natural orbital CC (DLPNO-CCSD(T)) has linear scaling (black). 
 
7.2 Intramolecular Interactions Energies 
 
Table 4 shows intramolecular interactions calculated with symmetry-adapted perturbation theory, 
F/I-SAPT0. For each calculation the molecule was divided into three parts, the phenyl ring, a small 
bridge part, and the rest of the molecule. To avoid dividing the system over an amide bond, the cut 
was done after the carbonyl carbon of the Dap amino acid moiety. The divided parts are shown 
with coloring in Figure 7, where the norephedrine phenyl ring is colored in grey, the bridge part in 
yellow and the for the rest of the molecule the amino acids are colored with red, blue, purple and 
green. The intramolecular energy is divided into four parts, electrostatic, dispersion, exchange 
repulsion, and induction. The total interaction energy is more attractive in the trans-conformer after 
halogenation for both MMAE and F.  
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The halogen interacts with the Dil moiety of the molecule in the trans-form of the compound 
(Figure 10). This interaction explains the greater relative stability of the trans-form of the 
halogenated species. Electrostatic and dispersion interactions favor the trans-conformer more, and 
induction does not change much. Exchange energy difference changes to favor cis-conformer more 
than for the original; this is probably due to more repulsion between the electrons of the halogen 
and the rest of the structure in the cis-conformer. Overall the total interaction energy goes from 
favoring the cis-form by -7.4 kJ/mol for original MMAE to favoring trans-form by +4.4 kJ/mol for 
F-MMAE and +4.2 kJ/mol for Cl-MMAE. For MMAF the values are -9.0 kJ/mol for the original 
to +3.3 for F-MMAF and +2.8 kJ/mol for Cl-MMAF. 
 
Table 4. Intramolecular interaction energies between the terminal phenyl ring and the four 
remaining peptides, based on a F/I-SAPT0 analysis. The interaction energy is divided into four 
parts, electrostatic, dispersion, exchange, and induction. Energy values are in kJ/mol. A positive 
value means that the equilibrium favors trans-conformer. 
MMAE total electrostatic dispersion exchange induction 
original -7.4 -7.1 -8.5 +9.8 -1.7 
para F +4.4 +8.1 -1.4 -2.3 +0.0 
para Cl +4.2 +6.4 -4.8 +3.7 -1.1 
      
MMAF total electrostatic dispersion exchange induction 
original -9.0 -8.3 -9.7 +10.9 -1.9 
para F +3.3 +4.2 -6.4 +6.6 -1.1 
para Cl +2.8 +4.4 -5.6 +5.1 -1.1 
 
Next, we take a closer look at the different energy-components of the intramolecular interaction 
between the terminal phenyl group and the rest of the auristatin. The electrostatic interactions are 
more attractive in the halogenated trans-conformers, whereas for the original auristatins the cis-
conformers experience greater electrostatic interactions. For MMAE the electrostatic difference 
between cis/trans goes from -7.1 kJ/mol for the original to +8.1 kJ/mol for F-MMAE (change of 
15.2 kJ/mol) and +6.4 kJ/mol for Cl-MMAE (change of 13.5 kJ/mol). For MMAF the values are -
8.3 kJ/mol for the original to +4.2 for fluorinated and +4.4 kJ/mol for chlorinated species (change 
of 12.5 and 12.7 kJ/mol respectively).  
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For the original molecules, dispersion favors the cis-conformer (-8.5 kJ/mol for MMAE and -9.7 
kJ/mol for MMAF). For the halogenated species, this changes, and dispersion does not favor the 
cis-conformer as much as before: -1.4 kJ/mol for F-MMAE, -4.8 kJ/mol for Cl-MMAE, -6.4 kJ/mol 
for F-MMAF, and -5.6 kJ/mol for Cl-MMAF. Thus, dispersion still favors the cis-conformer, but 
not as much as for the original molecules. The induction energy difference between the cis- and 
trans-conformers for each molecule remains almost the same.  
 
For the original molecules, there is relatively more exchange repulsion in the cis-conformer than 
trans-conformer, since in the more compact cis-conformer the atoms are closer together and repel 
each other more. Halogenation changes the small hydrogen to a bigger atom with more electrons; 
this creates more e-e repulsion for both of the conformers. For the relative cis/trans exchange 
energy this means that the for the original molecules the trans-conformer is favored more than in 
the halogenated species; in the case of F-MMAE, the cis-conformer actually experiences less steric 
repulsion than the trans-conformer.  
 
Thus, it can be concluded that while halogenation does induce unfavorable e-e repulsion, this is 
more than compensated for by favorable electrostatic and dispersion interactions, so that the overall 
interaction energy is more attractive for the trans-conformer.  
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Figure 10. Non-covalent interaction plot for MMAE and Cl-MMAE trans-conformers. The green 
areas indicate intramolecular dispersion interactions. Compared to the original MMAE there is 
more interaction energy between the benzene ring and the rest of the structure in Cl-MMAE due 
to halogenation. Especially the chlorine interacts with the Dil amino acid. Figure from 57. 
 
The noncovalent interactions can be plotted as shown in Figure 10. The green indicates that there 
are dispersion interactions (the theory in section 4.8). In Cl-MMAE there is more interactions 
between the halogenated benzene ring and the rest of the structure, compared to the original 
MMAE. 
 
7.3 Docking 
 
A docking study of MMAE, F-MMAE, and Cl-MMAE binding to microtubules was performed 
using the AutoDock protocol. The lowest energy binding poses for each ligand as well as the 
original crystal structure of the MMAE molecule at the tubulin binding site are shown in Figure 
11. AutoDock places MMAE very close to the experimental crystal structure MMAE ligand. For 
the modified structures, the halogenated phenyl rings have moved slightly so that the halogen can 
fit at the binding site. The benzene rings of the fluorinated and chlorinated species turn in different 
directions. The lowest energy poses of both F-MMAE and Cl-MMAE have a 1.1 kJ/mol weaker 
binding energy than the original MMAE. The mean binding energy of lowest binding energy 
clusters of both F-MMAE and Cl-MMAE were also weaker, by 1.5 and 1.8 kJ/mol, respectively. 
This suggests that the halogenated MMAE structures bind slightly weaker than the original 
37 
 
molecule, but the change is small. It should also be noted that the protein structure that was used is 
the MMAE-tubulin crystal structure which might favor the original molecule since the protein was 
crystallized with the ligand at the binding pocket. Overall, the docking indicates that halogenation 
of the auristatins does not change binding much. Thus, it can be assumed that the modified 
molecules would bind to tubulin in reality as well. 
 
 
Figure 11. Docking of MMAE, F-MMAE and Cl-MMAE with AutoDock shows how the 
halogenated phenyl ring moves slightly to so that the halogen can fit in the binding pocket. The 
original crystal structure ligand MMAE is shown in dark green, MMAE docked with AutoDock is 
shown in terracotta, Cl-MMAE in light blue and F-MMAE in brown. The halogen atoms are 
colored with light green, oxygens with red, hydrogens with white and nitrogens with blue. The 
protein carbons are colored in pink and styled as sticks. 
 
7.4 Error Sources 
 
For the isomer energy differences studied here, high accuracy is crucial. Already a 1 kcal/mol 
(4.184 kJ/mol) energy difference leads to Boltzmann distribution of 84:16. Thus, the error in energy 
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needs to be small in order to obtain meaningful distribution. The focus here is in the relative energy 
difference between the cis- and trans-conformers. Thus, to some degree, error cancellation and 
systematic errors that are practically of equal magnitude for the two isomers simplifies the task of 
obtaining accurate final equilibrium energies. In this section we take a look at some potential 
sources of errors and uncertainties in the presented calculations. 
 
The DLPNO-CC calculation may be done with different settings, Loose-, Normal- or TightPNO.91  
These setting change various thresholds that control when a full CCSD(T) calculation will be 
performed for a specific electron-electron interaction, and when it will be approximated at a lower 
level of theory. Previously, it has been demonstrated that on average, one can expect an accuracy 
of ca 4 kJ/mol and 1 kJ/mol compared to canonical CCSD(T), using the NormalPNO and 
TightPNO setting, respectively.90, 91 In order to investigate how the different settings affect the 
results in the present case, we calculated the DLPNO-CCSD(T) cis-trans energy difference for 
MMAE with Normal- and TightPNO settings. The results are shown in Table 5. 
 
Table 5. DLPNO-CCSD(T) calculations with different basis sets and Normal- and TightPNO 
settings for MMAE. The values are in kJ/mol.  
MMAE DLPNO-CCSD(T) with different basis sets cis - trans, kJ/mol 
NormalPNO [T,Q]ZVPPD extrapolation -5.6 
 TZVPP -7.5 
 QZVPP -7.2 
  [T,Q]ZVPP extrapolation -7.1 
TightPNO TZVPP -9.9 
 QZVPP -9.8 
 [T,Q]ZVPP extrapolation -9.9 
 
The TZVPP basis set has fewer basis functions than the QZVPP basis set, and thus the calculation 
with the QZ basis set takes electron correlation better into account since the orbitals are described 
more accurately. With TightPNO settings, the cis-conformer is favored more than for the 
NormalPNO settings. Comparing this to experimental values, results obtained by the looser 
thresholds of the NormalPNO settings deviate less from the experimental values; -7.1 kJ/mol for 
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NormalPNO and -9.9 kJ/mol for TightPNO. When we use diffuse functions the cis/trans difference 
agrees even better with experiment; for calculations with NormalPNO settings the energy 
difference is -5.6 kJ/mol using the [T,Q]ZVPPD basis set in comparison to -7.1 kJ/mol for the 
[T,Q]ZVPP basis set extrapolation without diffuse functions.  
 
Here, it is appropriate to note that in our study57 we erroneously state that the energies calculated 
at DLPNO-CCSD(T) level were done using the TightPNO settings, while they in fact were done 
with the NormalPNO settings. In any case, the excellent agreement of results calculated with 
NormalPNO settings with the experimental values of the original auristatins indicate that the 
chosen level of theory is sound. The small difference to the TightPNO results, which is in line with 
previous studies, does indicate that there is some amount of error cancellation involved.  
 
The largest error sources can be estimated to be the enthalpy/entropy and solvation corrections. In 
this work, the Gibbs free energy was approximated from harmonic vibrational frequencies. Thus, 
for example, methyl group rotations are approximated as vibrations. For solvation we used a 
continuum solvent model instead of explicit water molecules. It can be assumed that the 
translational, rotational and vibrational motions contribute to the energy a different amount in gas 
and solution phase.142 Thus, the solvation energy was calculated by adding the energy calculated 
using gas phase structures and frequencies to solvation energy calculated using COSMO.143 In 
some cases, especially when the gas and solution phase structures differ significantly, using 
solution phase vibrational frequencies to obtain solvation energy may be more accurate than the 
approximations used here.144  
 
Overall, the accuracy of the computational models used here is quite good. Computational methods 
are usually not accompanied by error bars and estimating the accuracy of a given calculation needs 
to be based on comparisons to either more accurate calculations or experiment. Where a point of 
reference is lacking, as in the case of the halogenated auristatins in this work, an educated guess is 
often as good as it gets. Here we have shown that the MP2 and CC level calculations agree well 
with experiment, as the cis/trans-equilibrium results are within 1 kJ/mol of experimental values. A 
priori, there is no reason to suspect that the errors for the halogenated species would be notably 
larger. 
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8 Conclusions and Outlook 
 
We have presented a novel approach for increasing the potency of the auristatin cancer drug family; 
shifting the conformational equilibrium from the biologically inactive toward the active 
conformation. While other modifications to the auristatins have been made before, they are based 
on different design strategies, with a focus on e.g., lipophilicity, delivery, or affinity to tubulins. 
 
Here, we have shown that a simple halogenation at the para-position of the C-terminal phenyl ring 
of the auristatins has the desired effect on the cis/trans-equilibrium.  As the proposed changes in 
the structure are (relatively) small, the synthesis should be relatively easy. We have shown, using 
docking studies, that the modified molecules should bind to the tubulin in a similar manner as the 
original, unmodified MMAE and MMAF. The added group is quite stable and addition of fluorine 
and chlorine to a drug molecule is a widely used drug modification strategy.  
 
The goal of the study was to changes the cis/trans-equilibrium so that more of the molecule would 
be in the active trans-conformer than for the original MMAE and MMAF. This was achieved and 
the same result can be seen on all different computational theory levels. In the case of DFT, the 
cis/trans-equilibrium of the modified structures still favors the cis-conformer, but significantly less 
than for the original molecules. At MP2 and CC level the equilibrium changes to favor the trans-
conformer. Still, the change in relative energies between the originals and modified structures is of 
the same magnitude on all levels of theory.  
 
As can be seen for the intramolecular interaction energy analysis (Table 4) and non-covalent 
interactions plot (Figure 10), the halogen creates and increases existing favorable interactions in 
the trans-conformer. The NCI plot shows that there is new interaction between the halogen and Dil 
amino acid.  
 
In conclusion, halogenation of the auristatin benzene ring para-position changes the cis/trans-
equilibrium to favor the trans-conformation. This is significant for Cl-MMAF, F-MMAF and F-
MMAE as 94, 90 and 79 % of the molecule is in the trans-form (respectively). Next, based on this 
study, modified auristatins will be synthesized and the cis/trans-equilibrium will be measured. 
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Also, the biological activity will be measured in cancer-cell lines. Auristatins modified using the 
presented design strategy have the potential to be developed into new ADC-drugs. 
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